382 PHASE-III Randomized monocentric controlled trial comparing clinical and cost-effectiveness analysis of botulinum toxin uterine injections versus placebo for severe dysmenorrhea and chronic pelvic pain from uterine origin after standard therapeutic failure - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue European Journal of Obstetrics & Gynecology and Reproductive Biology Année : 2022

382 PHASE-III Randomized monocentric controlled trial comparing clinical and cost-effectiveness analysis of botulinum toxin uterine injections versus placebo for severe dysmenorrhea and chronic pelvic pain from uterine origin after standard therapeutic failure

Domaines

Sciences du Vivant [q-bio]

Christine Dupuis  : Connectez-vous pour contacter le contributeur

https://inserm.hal.science/inserm-04045112

Soumis le : vendredi 24 mars 2023-15:53:56

Dernière modification le : mercredi 15 novembre 2023-10:52:17

Fichier non déposé

Dates et versions

inserm-04045112 , version 1 (24-03-2023)

Identifiants

Citer

E. Bautrant, C. Lévêque, M. Santos, J. Kouame, O. Franké, et al.. 382 PHASE-III Randomized monocentric controlled trial comparing clinical and cost-effectiveness analysis of botulinum toxin uterine injections versus placebo for severe dysmenorrhea and chronic pelvic pain from uterine origin after standard therapeutic failure. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2022, 270, pp.e102-e103. ⟨10.1016/j.ejogrb.2021.11.333⟩. ⟨inserm-04045112⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM UNIV-AMU U1252
10 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More